4D Molecular Therapeutics vs MeiraGTx
4D Molecular Therapeutics reported revenue of $85 million in fiscal 2025, about the same as MeiraGTx's $81 million in fiscal 2025. 4D Molecular Therapeutics' revenue grew 230194.6% in its latest year, and MeiraGTx's grew 144.6%. 4D Molecular Therapeutics had an operating margin of -187.2%, against -130.2% at MeiraGTx. Free cash flow was −$110 million at 4D Molecular Therapeutics and −$50 million at MeiraGTx.
Side by side
| 4D Molecular Therapeutics | MeiraGTx | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $85M | $81M |
| Revenue growth | 230,194.6% | 144.6% |
| Revenue growth a year, last 5 years | 44.3% | 39.2% |
| Gross margin | — | — |
| Operating margin | −187.2% | −130.2% |
| Net margin | −164.4% | −140.3% |
| Free cash flow | −$110M | −$50M |
| Free cash flow margin | −128.7% | −61.7% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 7.4% | 15.2% |
| Last close | $12.23 | $9.18 |
| P/E at the last close | — | 11.5× |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
4D Molecular TherapeuticsMeiraGTx
Operating margin
Percent of revenue
4D Molecular TherapeuticsMeiraGTx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
4D Molecular TherapeuticsMeiraGTx
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the 4D Molecular Therapeutics and MeiraGTx pages.